APEIRON Biologics AG, Vienna Austria, engaged in cancer immunotherapy
APN311 (dinutuximab beta): anti-GD2 antibody for treatment of neuroblastoma. Marketing approval in the EU in May 2017. Licensed to EUSA Pharma
APN301: anti-GD2 antibody-IL2 fusion in Phase I/II, intratumoral delivery, in situ vaccination
APN401: individual cellular therapy based on intracellular checkpoint cbl-b; ex-vivo silencing of cbl-b in PBMC and re-administration of activated cells. Phase I completed
APN411, -421, -431: low molecular weight drugs in checkpoint blockade, preclinical (APN411 pursued with Evotec and Sanofi)